Resources

August 21, 2023 | Posters & Presentations
ASH41020, A Novel Hydroxyl Dendrimer CSF1R Tyrosine Kinase Inhibitor ‘Dendranib’ Nanomedicine, Polarizes Macrophages Toward an Anti-Inflammatory Phenotype and Improves Disease Severity in a Mouse Model of Multiple Sclerosis
May 22, 2023 | Publications
Clinical Radiosynthesis and Translation of [ 18F]OP-801: A Novel Radiotracer for Imaging Reactive Microglia and Macrophages
April 24, 2023 | Posters & Presentations
Oral Formulation Development of the Anti-Angiogenesis Drug D-4517.2 to Treat Age-related Macular Degeneration (wet AMD) and Diabetic Macular Edema (DME)
April 18, 2023 | Posters & Presentations
A Potent Macrophage Switching Drug D-4559 Reduces Tumor Growth in a Hepatocellular Carcinoma Mouse Model
April 1, 2023 | Publications
Targeted Nanomedicine: Ashvattha Therapeutics’ Path to Developing Hydroxyl Dendrimers
March 20, 2023 | Media
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
February 20, 2023 | Media
First patient enrolled in phase 1/2 study of hydroxyl dendrimer imaging agent
January 6, 2023 | Media
Economic Forecast 2023: New challenges in biotech’s ‘valley of death’
October 20, 2022 | Media
Biospace Movers & Shakers: Maravai, Predictive Oncology, Exagen and More Tap New Execs
September 29, 2022 | Posters & Presentations
WMIC 2022

Preclinical data demonstrating hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801 can be reproducibly synthesized and is suitable for human use.